QT interval prolongation: Prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France

Fundamental and Clinical Pharmacology

Volumn 25, Issue 4, 2011, Pages 503-510

  Perrin Terrin, Aurélie ^a   Pathak, Atul ^a   Lapeyre Mestre, Maryse ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Adverse drug reactions; Methadone; Opiate maintenance; QT interval; Torsades de pointes

Indexed keywords

ALCOHOL; BUPRENORPHINE; CALCIUM; CANNABIS; COCAINE; CODEINE; DIAMORPHINE; METHADONE; POTASSIUM;

ADULT; ALCOHOLISM; ARTICLE; CALCIUM BLOOD LEVEL; CANNABIS ADDICTION; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAPHY; FEMALE; FRANCE; HEART DISEASE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; RISK FACTOR; SUDDEN DEATH; TOBACCO; TOBACCO DEPENDENCE; TORSADE DES POINTES;

ADULT; DEATH, SUDDEN; DEATH, SUDDEN, CARDIAC; FEMALE; FRANCE; HEART DISEASES; HUMANS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PHARMACOVIGILANCE; PREVALENCE; RISK FACTORS; SMOKING; SUBSTANCE-RELATED DISORDERS; TORSADES DE POINTES; YOUNG ADULT;

EID: 79959991691     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00871.x     Document Type: Article

References (37)

1. Decerf J.A., Gressens B., Brohet C., Liolios A., Hantson P. Can methadone prolong the QT interval? Intensive Care Med. (2004) 30 1690-1691.
2. Gil M., Sala M., Anguera I. et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am. J. Cardiol. (2003) 92 995-997.
3. Piguet V., Desmeules J., Ehret G., Stoller R., Dayer P. QT interval prolongation in patients on methadone with concomitant drugs. J. Clin. Psychopharmacol. (2004) 24 446-448.
4. Walker P.W., Klein D., Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain (2003) 103 321-324.
5. Krantz M.J., Kutinsky I.B., Robertson A.D., Mehler P.S. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy (2003) 23 802-805.
6. Lucchini A., Barbaro G., Barbarini G. Methadone and QT prolongation in HIV-infected patients. Am. J. Cardiol. (2004) 94 147-148.
7. Krantz M.J., Mehler P.S. Methadone and QT prolongation: a dose-dependent effect? Am. J. Cardiol. (2004) 93 952.
8. European Agency for the Evaluation of Medicinal Products. EMEA public statement on the recommendation to suspend the marketing authorization for Orlaam (Levacetylmethadol) in the European Union. [accessed 2010 August 23].
9. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., Mehler P.S. Torsade de pointes associated with very-high-dose methadone. Ann. Intern. Med. (2002) 137 501-504.
10. Sticherling C., Schaer B.A., Ammann P., Maeder M., Osswald S. Methadone-induced Torsade de pointes tachycardias. Swiss Med. Wkly. (2005) 135 282-285.
11. Agence Française de Securite des Produits de Sante (Afssaps). Dear Doctor letter, January 2nd, 2007. .
12. Krantz M.J., Martin J., Stimmel B., Mehta D., Haigney M.C. QTc interval screening in methadone treatment. Ann. Intern. Med. (2009) 150 387-395.
13. Stimmel B., Lipski J., Swartz M., Donoso E. Electrocardiographic changes in heroins, methadone and multiple drug abuse: a postulated mechanism of sudden death in narcotic addicts. Proc. Natl Conf. Methadone Treat. (1973) 1 706-710.
14. Kornick C.A., Kilborn M.J., Santiago-Palma J. et al. QTc interval prolongation associated with intravenous methadone. Pain (2003) 105 499-506.
15. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. (2005) 26 119-124.
16. Katchman A.N., McGroary K.A., Kilborn M.J. et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J. Pharmacol. Exp. Ther. (2002) 303 688-694.
17. Rendig S.V., Amsterdam E.A., Henderson G.L., Mason D.T. Comparative cardiac contractile actions of six narcotic analgesics: morphine, meperidine, pentazocine, fentanyl, methadone and l-alpha-acetylmethadol (LAAM). J. Pharmacol. Exp. Ther. (1980) 215 259-265.
18. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA (2001) 285 45.
19. Observatoire Français des Drogues et Toxicomanies. Données nationales, Séries statistiques. .
20. Emmanuelli J., Desenclos J.C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction (2005) 100 1690-1700.
21. Molokhia M., Pathak A., Lapeyre-Mestre M. et al. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br. J. Clin. Pharmacol. (2008) 66 386-395.
22. Pearson E.C., Woosley R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol. Drug Saf. (2005) 14 747-753.
23. Bégaud B., Martin K., Haramburu F., Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA (2002) 288 1588.
24. Agence Française de Securite Sanitaire des Produits de sante. Repertoire des Spécialités Pharmaceutiques. Summary product characteristics of methadone. (last checked on 26th January 2010).
25. Cruciani R.A., Sekine R., Homel P. et al. Measurement of QTc in patients receiving chronic methadone therapy. J. Pain Symptom Manage. (2005) 29 385-391.
26. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur. Addict. Res. (2005) 11 44-49.
27. Martell B.A., Arnsten J.H., Krantz M.J., Gourevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am. J. Cardiol. (2005) 95 915-918.
28. Ehret G.B., Voide C., Gex-Fabry M. et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch. Intern. Med. (2006) 166 1280-1287.
29. Fonseca F., Marti-Almor J., Pastor A. et al. Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depend. (2009) 99 327-332.
30. Krantz M.J., Lowery C.M., Martell B.A., Gourevitch M.N., Arnsten J.H. Effects of methadone on QT-Interval dispersion. Pharmacotherapy (2005) 25 1523-1529.
31. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. (2002) 25 263-286.
32. Tosaka T., Casimiro M.C., Rong Q. et al. Nicotine induces a long QT phenotype in Kcnq1-deficient mouse hearts. J. Pharmacol. Exp. Ther. (2003) 306 980-987.
33. Fanoe S., Hvidt C., Ege P., Jensen G.B. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart (2007) 93 1051-1055.
34. Anchersen K., Clausen T., Gossop M., Hansteen V., Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction (2009) 104 993-999.
35. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. (2008) 16 CD002207.
36. Baker J.R., Best A.M., Pade P.A., McCance-Katz E.F. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann. Pharmacother. (2006) 40 392-396.
37. Krantz M.J., Mehler P.S. QTc prolongation: methadone's efficacy-safety paradox. Lancet (2006) 368 556-557.